You are here
This clinical trial is closed
Lead Country: England (also active in Scotland and Northern Ireland and Wales)
Current Status: Closed – in follow-up
Closure Date: 3 August 2013
Global Sample Size: 810
Global Recruitment to Date: 100%
SPIRIT2 is a Phase III, multicentre, open-label, prospective randomised trial comparing imatinib 400 mg daily versus dasatinib 100 mg daily in patients with newly-diagnosed chronic phase Chronic Myeloid Leukaemia (CML).